Ventyx Biosciences reported Phase II data showing its oral NLRP3 inhibitor VTX‑3232 produced dramatic reductions in inflammatory biomarkers, including a roughly 78% drop in hsCRP versus placebo, and improvements in IL‑6, Lp(a) and liver inflammation markers. The safety profile was comparable to placebo and the company highlighted potential cardiovascular indications despite limited weight‑loss effects. Markets reacted, sending Ventyx shares sharply higher and prompting industry speculation about partnership or acquisition interest for an oral inflammasome inhibitor.